Da2Ppv+L*4 (Orig S-P Us) Lv+Kb

Verify with FDA CVM →

248 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
248
Total Reports
34
Deaths Reported
1370.0%
Death Rate

Active Ingredients

Da2Ppv+L*4 (Orig S-P Us) Lv+Kb

Administration Routes

SubcutaneousUnknownSubconjunctivalOther

Species Affected

Dog 247
Human 1

Most Affected Breeds

Crossbred Canine/dog 68
Shepherd Dog - German 13
Terrier (unspecified) 12
Retriever - Golden 10
Retriever - Labrador 9
Shih Tzu 8
Pit Bull 8
Siberian Husky 7
Boxer (German Boxer) 7
Terrier - Yorkshire 6

Most Reported Reactions

Vomiting 70
Emesis (multiple) 49
Lethargy (see also Central nervous system depression in 'Neurological') 44
Diarrhoea 27
Seizure NOS 24
Death 20
Fever 19
Leucocytosis NOS 17
Other abnormal test result NOS 14
Death by euthanasia 14
Anorexia 13
Shaking 13

Outcome Breakdown

Recovered/Normal
101 (40.6%)
Ongoing
87 (34.9%)
Outcome Unknown
23 (9.2%)
Died
20 (8.0%)
Euthanized
14 (5.6%)
Recovered with Sequela
4 (1.6%)

Data Summary

Metric Value
Total adverse event reports 248
Reports involving death 34
Case-fatality rate (reported events) 1370.0%
Distinct species in reports 2
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Da2Ppv+L*4 (Orig S-P Us) Lv+Kb Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 248 adverse event reports referencing Da2Ppv+L*4 (Orig S-P Us) Lv+Kb, including 34 reports in which the animal died — a 1370.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Da2Ppv+L*4 (Orig S-P Us) Lv+Kb. Reported administration routes include Subcutaneous, Unknown, Subconjunctival, Other. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Da2Ppv+L*4 (Orig S-P Us) Lv+Kb reports are Dog (247 reports), Human (1 reports), with Dog accounting for the largest share. Within those species, Crossbred Canine/dog (68), Shepherd Dog - German (13), Terrier (unspecified) (12) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Da2Ppv+L*4 (Orig S-P Us) Lv+Kb are Vomiting (70), Emesis (multiple) (49), Lethargy (see also Central nervous system depression in 'Neurological') (44), Diarrhoea (27). Of the 249 reports with a coded outcome, Recovered/Normal is the leading category at 40.6%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Da2Ppv+L*4 (Orig S-P Us) Lv+Kb.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial